GWAS applied to heart failure: bigger will be better...eventually.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Relationship of disease-associated gene expression to cardiac phenotype is buffered by genetic diversity and chromatin regulation.Physiological genomics · 2016
   Article
2. Advances in the epidemiology of heart failure and left ventricular remodeling.Circulation · 2011
   Review

Corrections and comments

• Comment on
  Genomic variation associated with mortality among adults of European and African ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium.2010
• Comment on
  Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.2010

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as